Drug intelligence / Profile preview

aceclofenac + paracetamol

Development stage: Unknown
Lead developer: Wellmed Pharma
Modality: Small Molecules
Administration: Oral

Overview

**ALOPOR** is a Wellmed Pharma branded fixed-dose oral suspension containing aceclofenac 50 mg and paracetamol 125 mg per labeled dose. Aceclofenac is a small-molecule nonsteroidal anti-inflammatory drug that reversibly inhibits cyclooxygenase enzymes, reducing prostaglandin-mediated pain and inflammation. Paracetamol is a small-molecule analgesic and antipyretic whose therapeutic activity is associated with inhibition of prostaglandin synthesis, primarily within the central nervous system. The combination is marketed for symptomatic relief of pain, inflammation, and fever.

Brand names: ALOPOR
Other names: aceclofenac + acetaminophen

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on aceclofenac + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aceclofenac + paracetamol.

Explore the full profile